Company overview
Aqdot develops supramolecular chemistry solutions using patented AqFresh™ technology based on cucurbiturils for molecule capture, holding, and controlled release. In pharmaceuticals, it supports encapsulation platforms for controlled release strategies and offers ingredients like Aq™Bit and AqStar™ M1 with Platinum Material Health Certificates for safer chemical applications. The company licenses its technology to manufacturers, enabling innovations in drug delivery, pollutant capture, and sustainable production.
Aqdot is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include supramolecular chemistry, encapsulation technology, controlled release pharma, aqfresh technology, cucurbiturils pharma.
Structured facts
- Website
- https://aqdot.com
- Markets served
- United States & Americas
- Keywords
- supramolecular chemistry, encapsulation technology, controlled release pharma, aqfresh technology, cucurbiturils pharma
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What pharmaceutical capabilities does Aqdot offer?
- Aqdot provides a novel encapsulation platform using microfluidic droplets and supramolecular host-guest interactions for controlled release in pharmaceuticals, protected by four patents.
- What regulatory certifications do Aqdot products have?
- Aq™Bit and AqStar™ M1 have achieved Platinum level Material Health Certificates from the Cradle to Cradle Products Innovation Institute, confirming no risks to humans or the environment at concentrations of 100 ppm or above.
- What are Aqdot's geographic operations and partnerships?
- Headquartered in Cambridge, England, Aqdot expanded to the U.S. in 2019 and partners globally, including with Clariant for laundry and dishwash applications using AqFresh™ technology.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
